Clinical Study

Otsuka Tolvaptan Open Label Rollover Study For Adpkd

Posted Date: Dec 26, 2017

  • Investigator: Shashi Kant
  • Co-Investigator: Karen Case
  • Specialties: Kidney Disease, Nephrology
  • Type of Study: Drug

Tolvaptan is being studied as a possible treatment for autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a disease that causes kidney cysts (cysts are like fluid-filled balloons), worsening kidney function, blood in the urine, kidney pain, high blood pressure, kidney stones, kidney infections, and cysts in the liver or other parts of the body and sometimes heart or blood vessel abnormalities. The kidneys of patients with ADPKD respond abnormally to a hormone in the bloodstream called vasopressin. This abnormal response can cause the cysts in the kidneys, associated with the disease, to grow more quickly. Tolvaptan blocks the effect of this hormone in the kidneys meaning that it can slow the growth of the kidney cysts when taken for a long time.


Inclusion: Previous Participation In Otsuka 156-13-210 Double Blind Study, Egfr >= 20 Exclusion: Hepatic Impairment, Breast-Feeding Or Pregnant, Need For Chronic Diuretics


Kidney Disease, Adpkd, Cysts, Nephrology, Null

For More Information:

Karen Case, Ccrp

  • Search Clinical Studies

  • Research in the News

    Enhanced Recovery Program for Colorectal Surgery Patients Reduces Costs

    A standardized protocol for managing patients for the duration of colorectaloperations not only improved clinical outcomes, but also it significantlyreduced hospital costs.